The efficacy of cancer immunotherapy depends on the fine interplay between tumoral immune checkpoints and host immune system. However, the up-to-date clinical performance of checkpoint blockers in ...
Expert Rev Anticancer Ther. 2009;9(9):1305-1316. Very recently, the addition of bortezomib to chemotherapy was evaluated in DLBCL patients relapsing after R-CHOP. [49] To test the hypothesis that ...
2011;4(5):551-562. In addition, there are several trials currently examining the combination of bortezomib and histone deacetylase inhibitors (HDACi) or 5-azacitidine in the relapsed refractory T ...
Recent investigations have disclosed various inhibitors of the NLRP3 inflammasome pathway which were validated through in vitro studies and in vivo experiments in animal models of NLRP3-associated ...
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China Department of Medicinal Chemistry, School ...
Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia
Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China Jiangsu Key Laboratory of Drug Design and ...
Proton pump inhibitors (PPI) use is associated with increased risk of enteric infections, in particular with a 65% increase in incidence of Clostridium difficile infection. PPI is one of the most ...
In this useful study, the authors tested a novel approach to eradicate the HIV reservoir by constructing a herpes simplex virus (HSV)-based therapeutic vaccine designed to reactivate HIV from latently ...
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback